|Systematic (IUPAC) name|
N-(4-(4,5-dihydro-2-methylimidazo[4,5-d]benzazepin- 6(1H)-yl)carbonyl)phenyl)- (1,1'-biphenyl)-2-carboxamide
|ATC code||C03XA02 (WHO) |
|Molar mass||498.583[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
Conivaptan (YM 087, brand name Vaprisol) is a non-peptide inhibitor of antidiuretic hormone (vasopressin receptor antagonist). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH), and there is some evidence it may be effective in heart failure. It is marketed by Astellas Pharma Inc.
Conivaptan has not been approved by the FDA for the treatment of decompensated congestive heart failure. However, in theory, vasopressin receptor antagonism would be particularly useful in this setting, and an initial study shows that it has some promise.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
|45px||This hormonal preparation article is a stub. You can help ssf by expanding it.|
|30px||This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it.|
- WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. Retrieved 2008-09-05.
- Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.